Argatroban is a synthetic direct thrombin inhibitor with a relative short elimination half-life of
45 minutes and elimination which is predominantly performed via hepatic metabolism …

Heparin-induced thrombocytopenia (HIT) is a rare but potentially severe complication of
heparin therapy that is strongly associated with venous and arterial thrombosis (HIT and …

Argatroban is a synthetic, small-molecule direct thrombin inhibitor that is approved in the
USA, the EU and Japan for prophylaxis or treatment of thrombosis in patients with heparin …

Argatroban is a small molecule direct thrombin inhibitor. The main attributes of this synthetic
drug are its rapid onset of anti-thrombin action, rapid reversibility of its anticoagulant effect …

Pharmacological strategies aimed at the prevention of thrombotic complications are in
continuous development. Argatroban is a synthetic small molecule derived from l-arginine …

Abstract▴ Argatroban is a direct thrombin inhibitor synthesised to bind to the catalytic site of
the thrombin molecule. It binds rapidly and reversibly to both clot-bound and soluble …

Argatroban, a direct thrombin inhibitor, has been used in Japan since the early 1980's and
was recently approved for use in the United States for patients with heparin-induced …

Argatroban, a direct thrombin inhibitor, effectively inhibits free and clot-bound thrombin
without the need of a cofactor and exerts dose-dependent anticoagulant effects that are …

Antithrombotic and antiplatelet therapies are the cornerstones of management of
cardiovascular disorders today. Due to the safety and efficacy limitations of the classic …

Heparin remains the most commonly used anticoagulant in the treatment of patients with
acute vascular syndromes, including myocardial infarction, unstable angina and ischaemic …